Literature DB >> 20513136

Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity.

Logan C Walker1, Phillip J Whiley, Fergus J Couch, Daniel J Farrugia, Sue Healey, Diana M Eccles, Feng Lin, Samantha A Butler, Sheila A Goff, Bryony A Thompson, Sunil R Lakhani, Leonard M Da Silva, Sean V Tavtigian, David E Goldgar, Melissa A Brown, Amanda B Spurdle.   

Abstract

Missense substitutions in high-risk cancer susceptibility genes create clinical uncertainty in the genetic counseling process. Multifactorial likelihood classification approaches and in vitro assays are useful for the classification of exonic sequence variants in BRCA1 and BRCA2, but these currently rely on the assumption that changes in protein function are the major biological mechanism of pathogenicity. This study investigates the potentially pathogenic role of aberrant splicing for exonic variants predicted to encode missense substitutions using patient-derived RNA. No splicing aberrations were identified for BRCA1c.5054C>T and BRCA2c.7336A>G, c.8839G>A, and c.9154C>T. However, RT-PCR analysis identified a major splicing aberration for BRCA1c.4868C>G(p.Ala1623Gly), a variant encoding a missense substitution considered likely to be neutral. Splicing aberrations were also observed for BRCA2c.7988A>T(p.Glu2663Val) and c.8168A>G(p.Asp2723Gly), but both variant and wildtype alleles were shown to be present in full-length mRNA transcripts, suggesting that variant protein may be translated. BRCA2 protein function assays indicated that BRCA2p.Glu2663Val, p.Asp2723Gly and p.Arg3052Trp missense proteins have abrogated function consistent with pathogenicity. Multifactorial likelihood analysis provided evidence for pathogenicity for BRCA1 c.5054C>T(p.Thr1685Ile) and BRCA2c.7988A>T(p.Glu2663Val), c.8168A>G(p.Asp2723Gly) and c.9154C>T(p.Arg3052Trp), supporting experimentally derived evidence. These findings highlight the need for improved bioinformatic prediction of splicing aberrations and to refine multifactorial likelihood models used to assess clinical significance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20513136      PMCID: PMC3021973          DOI: 10.1002/humu.21267

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  42 in total

1.  Functional assays for classification of BRCA2 variants of uncertain significance.

Authors:  Daniel J Farrugia; Mukesh K Agarwal; Vernon S Pankratz; Amie M Deffenbaugh; Dmitry Pruss; Cynthia Frye; Linda Wadum; Kiley Johnson; Jennifer Mentlick; Sean V Tavtigian; David E Goldgar; Fergus J Couch
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

2.  Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides.

Authors:  Liutao Du; Julianne M Pollard; Richard A Gatti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-26       Impact factor: 11.205

3.  Prediction and assessment of splicing alterations: implications for clinical testing.

Authors:  Amanda B Spurdle; Fergus J Couch; Frans B L Hogervorst; Paolo Radice; Olga M Sinilnikova
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

4.  Assessment of functional effects of unclassified genetic variants.

Authors:  Fergus J Couch; Lene Juel Rasmussen; Robert Hofstra; Alvaro N A Monteiro; Marc S Greenblatt; Niels de Wind
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

5.  Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications.

Authors:  Sean V Tavtigian; Graham B Byrnes; David E Goldgar; Alun Thomas
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

6.  A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.

Authors:  Douglas F Easton; Amie M Deffenbaugh; Dmitry Pruss; Cynthia Frye; Richard J Wenstrup; Kristina Allen-Brady; Sean V Tavtigian; Alvaro N A Monteiro; Edwin S Iversen; Fergus J Couch; David E Goldgar
Journal:  Am J Hum Genet       Date:  2007-09-06       Impact factor: 11.025

7.  Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals.

Authors:  Gene Yeo; Christopher B Burge
Journal:  J Comput Biol       Date:  2004       Impact factor: 1.479

8.  Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.

Authors:  Amanda B Spurdle; Sunil R Lakhani; Sue Healey; Suzanne Parry; Leonard M Da Silva; Ross Brinkworth; John L Hopper; Melissa A Brown; Davit Babikyan; Georgia Chenevix-Trench; Sean V Tavtigian; David E Goldgar
Journal:  J Clin Oncol       Date:  2008-04-01       Impact factor: 44.544

9.  Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?

Authors:  Paul K Lovelock; Amanda B Spurdle; Myth T S Mok; Daniel J Farrugia; Sunil R Lakhani; Sue Healey; Stephen Arnold; Daniel Buchanan; Fergus J Couch; Beric R Henderson; David E Goldgar; Sean V Tavtigian; Georgia Chenevix-Trench; Melissa A Brown
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

10.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.

Authors:  Sharon E Plon; Diana M Eccles; Douglas Easton; William D Foulkes; Maurizio Genuardi; Marc S Greenblatt; Frans B L Hogervorst; Nicoline Hoogerbrugge; Amanda B Spurdle; Sean V Tavtigian
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

View more
  29 in total

Review 1.  BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.

Authors:  D M Eccles; G Mitchell; A N A Monteiro; R Schmutzler; F J Couch; A B Spurdle; E B Gómez-García
Journal:  Ann Oncol       Date:  2015-07-07       Impact factor: 32.976

2.  Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes.

Authors:  Jean Christophe Théry; Sophie Krieger; Pascaline Gaildrat; Françoise Révillion; Marie-Pierre Buisine; Audrey Killian; Christiane Duponchel; Antoine Rousselin; Dominique Vaur; Jean-Philippe Peyrat; Pascaline Berthet; Thierry Frébourg; Alexandra Martins; Agnès Hardouin; Mario Tosi
Journal:  Eur J Hum Genet       Date:  2011-06-15       Impact factor: 4.246

3.  BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management.

Authors:  Noralane M Lindor; David E Goldgar; Sean V Tavtigian; Sharon E Plon; Fergus J Couch
Journal:  Oncologist       Date:  2013-04-24

4.  Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches.

Authors:  Lucia Guidugli; Hermela Shimelis; David L Masica; Vernon S Pankratz; Gary B Lipton; Namit Singh; Chunling Hu; Alvaro N A Monteiro; Noralane M Lindor; David E Goldgar; Rachel Karchin; Edwin S Iversen; Fergus J Couch
Journal:  Am J Hum Genet       Date:  2018-01-25       Impact factor: 11.025

5.  Functional evaluation of variants of unknown significance in the BRCA2 gene identified in genetic testing.

Authors:  Marie Heczkova; Eva Machackova; Peter Macinga; Eike Gallmeier; Monika Cahova; Julius Spicak; Milan Jirsa; Lenka Foretova; Tomas Hucl
Journal:  Cancer Biol Ther       Date:  2019-01-13       Impact factor: 4.742

Review 6.  Functional assays for analysis of variants of uncertain significance in BRCA2.

Authors:  Lucia Guidugli; Aura Carreira; Sandrine M Caputo; Asa Ehlen; Alvaro Galli; Alvaro N A Monteiro; Susan L Neuhausen; Thomas V O Hansen; Fergus J Couch; Maaike P G Vreeswijk
Journal:  Hum Mutat       Date:  2013-12-03       Impact factor: 4.878

7.  Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing.

Authors:  Phillip J Whiley; Miguel de la Hoya; Mads Thomassen; Alexandra Becker; Rita Brandão; Inge Sokilde Pedersen; Marco Montagna; Mireia Menéndez; Francisco Quiles; Sara Gutiérrez-Enríquez; Kim De Leeneer; Anna Tenés; Gemma Montalban; Demis Tserpelis; Toshio Yoshimatsu; Carole Tirapo; Michela Raponi; Trinidad Caldes; Ana Blanco; Marta Santamariña; Lucia Guidugli; Gorka Ruiz de Garibay; Ming Wong; Mariella Tancredi; Laura Fachal; Yuan Chun Ding; Torben Kruse; Vanessa Lattimore; Ava Kwong; Tsun Leung Chan; Mara Colombo; Giovanni De Vecchi; Maria Caligo; Diana Baralle; Conxi Lázaro; Fergus Couch; Paolo Radice; Melissa C Southey; Susan Neuhausen; Claude Houdayer; Jim Fackenthal; Thomas Van Overeem Hansen; Ana Vega; Orland Diez; Rien Blok; Kathleen Claes; Barbara Wappenschmidt; Logan Walker; Amanda B Spurdle; Melissa A Brown
Journal:  Clin Chem       Date:  2013-11-08       Impact factor: 8.327

8.  BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.

Authors:  Amanda B Spurdle; Phillip J Whiley; Bryony Thompson; Bingjian Feng; Sue Healey; Melissa A Brown; Christopher Pettigrew; Christi J Van Asperen; Margreet G E M Ausems; Anna A Kattentidt-Mouravieva; Ans M W van den Ouweland; Annika Lindblom; Maritta H Pigg; Rita K Schmutzler; Christoph Engel; Alfons Meindl; Sandrine Caputo; Olga M Sinilnikova; Rosette Lidereau; Fergus J Couch; Lucia Guidugli; Thomas van Overeem Hansen; Mads Thomassen; Diana M Eccles; Kathy Tucker; Javier Benitez; Susan M Domchek; Amanda E Toland; Elizabeth J Van Rensburg; Barbara Wappenschmidt; Åke Borg; Maaike P G Vreeswijk; David E Goldgar
Journal:  J Med Genet       Date:  2012-08       Impact factor: 6.318

Review 9.  Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation.

Authors:  Alvaro N Monteiro; Peter Bouwman; Arne N Kousholt; Diana M Eccles; Gael A Millot; Jean-Yves Masson; Marjanka K Schmidt; Shyam K Sharan; Ralph Scully; Lisa Wiesmüller; Fergus Couch; Maaike P G Vreeswijk
Journal:  J Med Genet       Date:  2020-03-09       Impact factor: 6.318

10.  BRCA1 point mutations in premenopausal breast cancer patients from Central Sudan.

Authors:  Ida Biunno; Gitana Aceto; Khalid Dafaallah Awadelkarim; Annalisa Morgano; Ahmed Elhaj; Elgaylani Abdalla Eltayeb; Dafalla Omer Abuidris; Nasr Eldin Elwali; Chiara Spinelli; Pasquale De Blasio; Ermanna Rovida; Renato Mariani-Costantini
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.